ACURA PHARMACEUTICALS, INC: M&A transaction — Acura receives two $100K loans from AD Pharma; warns of possible operations halt if no further financing by Aug 2025

ACURA PHARMACEUTICALS, INC

Principal on secured note rises to $8,394,279 with ~$740K accrued interest; interest rate 5.25%.
Loans of $100K each on July 3 and July 18, 2025 from Abuse Deterrent Pharma, LLC (AD Pharma).
Without additional financing by early August 2025, company may furlough employees or seek bankruptcy protection.
AD Pharma owns ~65% of outstanding common stock (excludes warrant for 10M shares).
Funds used for day-to-day operations; no assurance of further financing.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $8,394,279 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $8,394,279
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of July 3, 2025 and July 18, 2025, we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma"). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $8,394,279 with accrued interest of approximately $740,000 as of July 21 2025, and bears interest at 5.25% ("Note").

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.1

ACURA PHARMACEUTICALS, INC completed an acquisition involving Abuse Deterrent Pharma, LLC.

Action: acquisition
Counterparty: Abuse Deterrent Pharma, LLC

Exact text from the filing

Item 2.01 – Completion of Acquisition or Disposition of Assets The contents of all Items 1.01 are incorporated herein by reference.

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-069258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.